Literature DB >> 17004108

The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation.

Anna Jakubowska1, Jacek Gronwald, Bohdan Górski, Tomasz Huzarski, Tomasz Byrski, Axel Benner, Jan Lubiński, Rodney J Scott, Ute Hamann.   

Abstract

The variable penetrance of breast cancer in BRCA1 mutation carriers suggests that other genetic or environmental factors modify breast cancer risk. The C to T transition in the 3' untranslated region of the prohibitin (PHB) gene alters mRNA function and has been shown to be associated with an increased breast cancer risk among young North-American women who have one first-degree relative with breast cancer. To investigate whether the PHB 3'UTR polymorphism acts as a modifier of hereditary breast cancer risk we performed a case-control study among female BRCA1 mutation carriers, which included 258 cases and 258 controls who were unaffected by ovarian cancer, in situ breast carcinoma or any other type of cancer. Controls were matched to cases by year of birth and BRCA1 mutation (5382insC, 300 T > G, 4153delA). Genotyping analysis was performed using RFLP-PCR. Odds ratios (OR) were calculated using conditional and penalised univariable and multivariable logistic regression. Multivariable penalised logistic regression revealed CT (OR(adj), 2.03; 95% CI, 1.17-3.59) and combined CT + TT (OR(adj), 2.12; 95% CI, 1.23-3.70) genotypes as significant modifiers of breast cancer risk. Breast cancer risk did not differ between carriers of the 300 T > G and 5382insC mutation. Our results suggest that the PHB 3'UTR T allele increases the risk of breast cancer in patients who are already at increased risk of disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17004108     DOI: 10.1007/s10549-006-9389-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  Association of 758 G/A polymorphism of 3'untranslated region of prohibitin with risk of gastric cancer.

Authors:  Fenfen Xiang; Zhenhua Ni; Yueping Zhan; Jian Xu; Rong Wu; Xiangdong Kang
Journal:  J Clin Lab Anal       Date:  2017-03-13       Impact factor: 2.352

2.  3' untranslated region 1630 C>T polymorphism of prohibitin increases risk of breast cancer.

Authors:  Lin Tang; Yunzhao Zhao; Weiwei Nie; Zexing Wang; Xiaoxiang Guan
Journal:  Onco Targets Ther       Date:  2013-03-09       Impact factor: 4.147

3.  Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study.

Authors:  A Jakubowska; D Rozkrut; A Antoniou; U Hamann; R J Scott; L McGuffog; S Healy; O M Sinilnikova; G Rennert; F Lejbkowicz; A Flugelman; I L Andrulis; G Glendon; H Ozcelik; M Thomassen; M Paligo; P Aretini; J Kantala; B Aroer; A von Wachenfeldt; A Liljegren; N Loman; K Herbst; U Kristoffersson; R Rosenquist; P Karlsson; M Stenmark-Askmalm; B Melin; K L Nathanson; S M Domchek; T Byrski; T Huzarski; J Gronwald; J Menkiszak; C Cybulski; P Serrano; A Osorio; T R Cajal; M Tsitlaidou; J Benítez; M Gilbert; M Rookus; C M Aalfs; I Kluijt; J L Boessenkool-Pape; H E J Meijers-Heijboer; J C Oosterwijk; C J van Asperen; M J Blok; M R Nelen; A M W van den Ouweland; C Seynaeve; R B van der Luijt; P Devilee; D F Easton; S Peock; D Frost; R Platte; S D Ellis; E Fineberg; D G Evans; F Lalloo; R Eeles; C Jacobs; J Adlard; R Davidson; D Eccles; T Cole; J Cook; A Godwin; B Bove; D Stoppa-Lyonnet; V Caux-Moncoutier; M Belotti; C Tirapo; S Mazoyer; L Barjhoux; N Boutry-Kryza; P Pujol; I Coupier; J-P Peyrat; P Vennin; D Muller; J-P Fricker; L Venat-Bouvet; O Th Johannsson; C Isaacs; R Schmutzler; B Wappenschmidt; A Meindl; N Arnold; R Varon-Mateeva; D Niederacher; C Sutter; H Deissler; S Preisler-Adams; J Simard; P Soucy; F Durocher; G Chenevix-Trench; J Beesley; X Chen; T Rebbeck; F Couch; X Wang; N Lindor; Z Fredericksen; V S Pankratz; P Peterlongo; B Bonanni; S Fortuzzi; B Peissel; C Szabo; P L Mai; J T Loud; J Lubinski
Journal:  Br J Cancer       Date:  2012-05-15       Impact factor: 7.640

4.  Cancer risk susceptibility loci in a Swedish population.

Authors:  Wen Liu; Xiang Jiao; Jessada Thutkawkorapin; Hovsep Mahdessian; Annika Lindblom
Journal:  Oncotarget       Date:  2017-11-25

5.  Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism.

Authors:  Anna Jakubowska; Jacek Gronwald; Janusz Menkiszak; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Axel Benner; Jan Lubiński; Rodney J Scott; Ute Hamann
Journal:  BMC Cancer       Date:  2008-04-08       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.